Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment.

BACKGROUND The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate annually to provide information on cancer rates and trends in the United States. This year's report updates statistics on the 15 most common cancers in the five major racial/ethnic populations in the United States for 1992-2002 and features population-based trends in cancer treatment. METHODS The NCI, the CDC, and the NAACCR provided information on cancer cases, and the CDC provided information on cancer deaths. Reported incidence and death rates were age-adjusted to the 2000 U.S. standard population, annual percent change in rates for fixed intervals was estimated by linear regression, and annual percent change in trends was estimated with joinpoint regression analysis. Population-based treatment data were derived from the Surveillance, Epidemiology, and End Results (SEER) Program registries, SEER-Medicare linked databases, and NCI Patterns of Care/Quality of Care studies. RESULTS Among men, the incidence rates for all cancer sites combined were stable from 1995 through 2002. Among women, the incidence rates increased by 0.3% annually from 1987 through 2002. Death rates in men and women combined decreased by 1.1% annually from 1993 through 2002 for all cancer sites combined and also for many of the 15 most common cancers. Among women, lung cancer death rates increased from 1995 through 2002, but lung cancer incidence rates stabilized from 1998 through 2002. Although results of cancer treatment studies suggest that much of contemporary cancer treatment for selected cancers is consistent with evidence-based guidelines, they also point to geographic, racial, economic, and age-related disparities in cancer treatment. CONCLUSIONS Cancer death rates for all cancer sites combined and for many common cancers have declined at the same time as the dissemination of guideline-based treatment into the community has increased, although this progress is not shared equally across all racial and ethnic populations. Data from population-based cancer registries, supplemented by linkage with administrative databases, are an important resource for monitoring the quality of cancer treatment. Use of this cancer surveillance system, along with new developments in medical informatics and electronic medical records, may facilitate monitoring of the translation of basic science and clinical advances to cancer prevention, detection, and uniformly high quality of care in all areas and populations of the United States.

[1]  A. Zaslavsky,et al.  Completeness of Information on Adjuvant Therapies for Colorectal Cancer in Population-Based Cancer Registries , 2003, Medical care.

[2]  C. Somkin,et al.  Cost of Care for Cancer in a Health Maintenance Organization , 1997, Health care financing review.

[3]  S. Edge,et al.  Treatment of early-stage breast cancer. , 1999, Current problems in cancer.

[4]  M. Thun,et al.  Tobacco use and cancer: an epidemiologic perspective for geneticists , 2002, Oncogene.

[5]  C. Lynch,et al.  Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Daniel S. Miller,et al.  Cancer incidence and mortality, 1973‐1995 , 1998 .

[7]  E. Feuer,et al.  Permutation tests for joinpoint regression with applications to cancer rates. , 2000, Statistics in medicine.

[8]  Gregory S. Cooper,et al.  Studying Radiation Therapy Using SEER-Medicare-Linked Data , 2002, Medical care.

[9]  A. Neugut,et al.  Survival Associated with 5-FluorouracilBased Adjuvant Chemotherapy among Elderly Patients with Node-Positive Colon Cancer , 2002, Annals of Internal Medicine.

[10]  W. Barlow,et al.  Prostate cancer treatment and ten-year survival among group/staff HMO and fee-for-service Medicare patients. , 1999, Health services research.

[11]  E. Perez-stable,et al.  Epidemiology of cancer among Hispanics in the United States. , 1995, Journal of the National Cancer Institute. Monographs.

[12]  Daniel S. Miller,et al.  The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer , 2000, Cancer.

[13]  Joseph V. Simone,et al.  Ensuring Quality Cancer Care , 1999 .

[14]  L. Bernstein,et al.  Rapidly rising breast cancer incidence rates among Asian‐American women , 2002, International journal of cancer.

[15]  G. Cooper,et al.  Use of SEER-Medicare Data for Measuring Cancer Surgery , 2002, Medical care.

[16]  M. Symons,et al.  Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. , 2003, Journal of the National Cancer Institute.

[17]  M. Weinstein,et al.  Who gets chemotherapy for metastatic lung cancer? , 2000, Chest.

[18]  A. Jemal,et al.  Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. , 2003, Journal of the National Cancer Institute.

[19]  Katherine L Kahn,et al.  Validity of cancer registry data for measuring the quality of breast cancer care. , 2002, Journal of the National Cancer Institute.

[20]  Peter H Gann,et al.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2002, Journal of the National Cancer Institute.

[21]  E. Feuer,et al.  Bowel surveillance patterns after a diagnosis of colorectal cancer in Medicare beneficiaries. , 2001, Gastrointestinal endoscopy.

[22]  J. Stanford,et al.  Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. , 1999, Journal of the National Cancer Institute.

[23]  Michael J Thun,et al.  Long‐term trends in cancer mortality in the United States, 1930–1998 , 2003, Cancer.

[24]  Joseph V. Simone,et al.  Enhancing Data Systems to Improve the Quality of Cancer Care , 2000 .

[25]  W. Pe,et al.  Cancer incidence in New York City Hispanics, 1982 to 1985. , 1991 .

[26]  C. Erlichman Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Jemal,et al.  Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival , 2004, Cancer.

[28]  T R Fleming,et al.  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. , 1990, The New England journal of medicine.

[29]  A. Jemal,et al.  Recent trends in lung cancer mortality in the United States. , 2001, Journal of the National Cancer Institute.

[30]  H M Rosenberg,et al.  Age standardization of death rates: implementation of the year 2000 standard. , 1998, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[31]  L. Kessler,et al.  Factors associated with surgical and radiation therapy for early stage breast cancer in older women. , 1996, Journal of the National Cancer Institute.

[32]  V. Shavers,et al.  Race/Ethnicity and the Intensity of Medical Monitoring Under ‘Watchful Waiting’ for Prostate Cancer , 2004, Medical care.

[33]  C. Begg,et al.  Impact of hospital volume on operative mortality for major cancer surgery. , 1998, JAMA.

[34]  B. Hankey,et al.  The surveillance, epidemiology, and end results program: a national resource. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[35]  K. Kahn,et al.  Developing a system to assess the quality of cancer care: ASCO's national initiative on cancer care quality. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Deborah Schrag,et al.  Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population , 2002, Medical care.

[37]  A. Neugut,et al.  Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: a population-based study. , 2001, Cancer journal.

[38]  S. Edge,et al.  Measuring and Predicting Surgeons’ Practice Styles for Breast Cancer Treatment in Older Women , 2001, Medical care.

[39]  K. Kerlikowske,et al.  Incidence of and treatment for ductal carcinoma in situ of the breast. , 1996, JAMA.

[40]  M. Weinstein,et al.  Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  C. Begg,et al.  Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection , 2003, Journal of surgical oncology.

[42]  Colin B Begg,et al.  Variations in morbidity after radical prostatectomy. , 2002, The New England journal of medicine.

[43]  L. Kessler,et al.  Medicare Payments from Diagnosis to Death for Elderly Cancer Patients by Stage at Diagnosis , 1995, Medical care.

[44]  A. Jemal,et al.  Contemporary Lung Cancer Trends among U.S. Women , 2005, Cancer Epidemiology Biomarkers & Prevention.

[45]  K. Kerlikowske,et al.  Detection of ductal carcinoma in situ in women undergoing screening mammography. , 2002, Journal of the National Cancer Institute.

[46]  C. Klabunde,et al.  Stage at diagnosis and treatment patterns among older women with breast cancer: an HMO and fee-for-service comparison. , 1999, JAMA.

[47]  Thomas J. Smith,et al.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  O. Brawley,et al.  Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  B. Edwards,et al.  A vision for cancer incidence surveillance in the United States , 2003, Cancer Causes & Control.

[50]  Ahmedin Jemal,et al.  Annual Report to the Nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden , 2002, Cancer.

[51]  C. Earle,et al.  Trends in the aggressiveness of cancer care near the end of life. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  M. Fay,et al.  Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  J. Fraumeni,et al.  Declining lung cancer rates among young men and women in the United States: a cohort analysis. , 1989, Journal of the National Cancer Institute.

[54]  C B Begg,et al.  Racial differences in the treatment of early-stage lung cancer. , 1999, The New England journal of medicine.

[55]  J. Warren,et al.  Can cancer registry data be used to study cancer treatment? , 2003, Medical care.

[56]  J. Stanford,et al.  Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. , 2004, Journal of the National Cancer Institute.

[57]  A. Neugut,et al.  Patterns and outcomes of chemotherapy for elderly patients with stage II ovarian cancer: a population-based study. , 2004, Gynecologic oncology.

[58]  V. Shavers,et al.  Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer , 2004, Journal of General Internal Medicine.

[59]  C. Muir,et al.  International Classification of Diseases for Oncology , 1990 .

[60]  Hyune-Ju Kim,et al.  Kim H-J, Fay MP, Feuer EJ, Midthune DN, ‘ Permutation tests for joinpoint regression with applications to cancer rates’. Statistics in Medicine 2000 19:335–351 , 2001 .

[61]  R D Etzioni,et al.  Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. , 1999, Medical care.

[62]  K. Kerlikowske,et al.  Is there a downside to elderly women undergoing screening mammography? , 1998, Journal of the National Cancer Institute.

[63]  J L Freeman,et al.  Accuracy and completeness of Medicare claims data for surgical treatment of breast cancer. , 2000, Medical care.

[64]  W. Barlow,et al.  Breast cancer survival and treatment in health maintenance organization and fee-for-service settings. , 1997, Journal of the National Cancer Institute.

[65]  W. Barlow,et al.  Survival and Treatment for Colorectal Cancer Medicare Patients in Two Group/Staff Health Maintenance Organizations and the Fee-for-Service Setting , 1999, Medical care research and review : MCRR.

[66]  E. Trimble,et al.  The NIH Consensus Conference on Ovarian Cancer: screening, treatment, and follow-up. , 1994, Gynecologic oncology.

[67]  B. Smedley,et al.  The unequal burden of cancer : an assessment of NIH research and programs for ethnic minorities and the medically underserved , 1999 .

[68]  Daniel S. Miller,et al.  Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. , 1999, Journal of the National Cancer Institute.

[69]  D. Buist,et al.  Cost comparison of mastectomy versus breast-conserving therapy for early-stage breast cancer. , 2001, Journal of the National Cancer Institute.

[70]  K. Kahn,et al.  Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  M. McMillen,et al.  Representativeness of the surveillance, epidemiology, and end results program data: recent trends in cancer mortality rates. , 1992, Journal of the National Cancer Institute.

[72]  Ruth Etzioni,et al.  Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. , 2004, Urology.

[73]  T. Fleming,et al.  Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  M. Barry,et al.  Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. , 1996, Journal of the National Cancer Institute.

[75]  E. Feuer,et al.  The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence declinein the United States , 1998, Cancer Causes & Control.

[76]  R A Stephenson,et al.  Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. , 2000, Journal of the National Cancer Institute.

[77]  K. Thorpe,et al.  Health insurance and spending among cancer patients. , 2003, Health affairs.

[78]  C. Begg,et al.  Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results--Medicare. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  A. Neugut,et al.  Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. , 2004, Gynecologic oncology.

[80]  J. Meyerhardt,et al.  Association of Hospital Procedure Volume and Outcomes in Patients with Colon Cancer at High Risk for Recurrence , 2003, Annals of Internal Medicine.

[81]  C. Begg,et al.  Age and adjuvant chemotherapy use after surgery for stage III colon cancer. , 2001, Journal of the National Cancer Institute.

[82]  A. Zaslavsky,et al.  Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  Ruth Etzioni,et al.  Estimating Health Care Costs Related to Cancer Treatment From SEER-Medicare Data , 2002, Medical care.

[84]  L. Clegg,et al.  Adjuvant therapy for breast cancer: practice patterns of community physicians. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  J. Mclaughlin,et al.  Comparability of the death certificate and the 1986 National Mortality Followback Survey. , 1993, Vital and health statistics. Series 2, Data evaluation and methods research.

[86]  H M Rosenberg,et al.  Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. , 2001, Journal of the National Cancer Institute.

[87]  E. Feuer,et al.  Impact of reporting delay and reporting error on cancer incidence rates and trends. , 2002, Journal of the National Cancer Institute.

[88]  A. Donabedian Evaluating the quality of medical care. 1966. , 1966, The Milbank quarterly.

[89]  N Urban,et al.  Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. , 1995, Journal of the National Cancer Institute.

[90]  E. Trimble,et al.  Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  J R Sugarman,et al.  Improving American Indian cancer data in the Washington State Cancer Registry using linkages with the Indian Health Service and tribal records , 1996, Cancer.

[92]  E. Feuer,et al.  Confidence intervals for directly standardized rates: a method based on the gamma distribution. , 1997, Statistics in medicine.

[93]  Robert B Wallace,et al.  Population variations in the initial treatment of non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  A. Neugut,et al.  Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  A. Neugut,et al.  Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  G. A. Alexander,et al.  Racial/ethnic patterns of cancer in the United States, 1988-1992. , 1996 .

[97]  H M Rosenberg,et al.  Comparability of cause of death between ICD-9 and ICD-10: preliminary estimates. , 2001, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[98]  Robert J. Mayer,et al.  National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.

[99]  M. Thun,et al.  A national framework for cancer surveillance in the United States , 2005, Cancer Causes & Control.

[100]  M. Weinstein,et al.  Impact of referral patterns on the use of chemotherapy for lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  Klein Rj,et al.  Age adjustment using the 2000 projected U.S. population. , 2001 .

[102]  N. Cobb,et al.  Cancer mortality among American Indians and Alaska Natives: regional differences, 1994-1998. , 2003 .

[103]  Colin B Begg,et al.  Adherence to surveillance among patients with superficial bladder cancer. , 2003, Journal of the National Cancer Institute.

[104]  P. Sorlie,et al.  Quality of death rates by race and Hispanic origin: a summary of current research, 1999. , 1999, Vital and health statistics. Series 2, Data evaluation and methods research.

[105]  D. Doering,et al.  Cervical cancer in Kentucky. , 2000, The Journal of the Kentucky Medical Association.

[106]  J. Stanford,et al.  Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  E. Gilpin,et al.  Smoking initiation by adolescent girls, 1944 through 1988. An association with targeted advertising. , 1994, JAMA.

[108]  E. Partridge,et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, New England Journal of Medicine.

[109]  D A Carr,et al.  Two new templates for epidemiology applications: linked micromap plots and conditioned choropleth maps. , 2000, Statistics in medicine.

[110]  J. Stanford,et al.  Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. , 2001, Journal of the National Cancer Institute.

[111]  C. Begg,et al.  Hospital and Surgeon Procedure Volume as Predictors of Outcome Following Rectal Cancer Resection , 2002, Annals of surgery.

[112]  B. Kramer,et al.  Trends and black/white differences in treatment for nonmetastatic prostate cancer. , 1998, Medical care.

[113]  C. Begg,et al.  Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  C. Begg,et al.  The Effect of Clustering of Outcomes on the Association of Procedure Volume and Surgical Outcomes , 2003, Annals of Internal Medicine.

[115]  E. Emanuel,et al.  Patterns of care studies: creating "an environment of watchful concern". , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  L. Kessler,et al.  Potential for Cancer Related Health Services Research Using a Linked Medicare‐Tumor Registry Database , 1993, Medical care.